COYA 302 Trial Launch

Coya Therapeutics launched a Phase 2 trial of COYA 302, a combo of a signaling molecule with abatacept, to slow amyotrophic lateral sclerosis over about six months. About 120 adults aged 18–75 with ALS diagnosed within the last two years will join across roughly 25 sites in the United States and Canada. Participants will be randomized to two doses or placebo for 24 weeks, then may join an extension.